Diabetes med lixisenatide may slow motor decline in Parkinson’s: Study
Treatment with lixisenatide, a medication approved for type 2 diabetes, significantly slowed the progression of motor symptoms in people with Parkinson’s disease in a Phase 2 clinical trial. Although gastrointestinal side effects such as nausea and vomiting were more common with the therapy, the findings support lixisenatide as a potential…